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Purpose: There is a paucity of information on the clinical efficacy and safety of the photoselective vaporization (PVP) of the prostate 
using the 180W lithium triborate (LBO) laser. We report on initial outcomes of PVP with the 180W laser, comparing the first 50 cases 
with the last 50 cases performed with the 120W LBO laser.
Methods: All cases performed by a single surgeon (HHW) have been prospectively maintained. The last 50 cases treated with the 
120W LBO laser (December 2009 to August 2010) were compared with the first 50 cases treated with the 180W LBO (July 2010 to June 
2011). Patient variables were recorded preoperatively and at 3 months postoperatively. Perioperative data was also recorded. 
Results: The 180W cases had a larger median transrectal ultrasound prostate volume (68 mL vs. 51 mL, P<0.05). For the 180W and 
120W LBO lasers, total operating time was 64.2 and 72.5 minutes (not significant [NS] at P=0.22), lasering time 49.6 and 54.6 minutes 
(NS, P=0.30) and energy utilisation 477.6 kJ and 377.9 kJ (P<0.05) respectively. When compared per gram of prostate tissue lasered, 
the 180W is quicker at 0.67 min/g vs. 1.0 min/g for the 120W laser. Complications using the Clavien-Dindo classification included 
5 grade 1 complications and 3 grade 3b (bladder neck contractures) with the 180W LBO laser. The 120 W LBO laser had 4 grade 1 
complications and 1 grade 2.
Conclusions: There is little change in clinical outcomes with the transition from 120W to 180W LBO PVP with an already experienced 
PVP surgeon. The 180W LBO laser appears to have impacted upon patient selection with significantly increased prostate size and 
associated with increased energy utilisation. There appears to be a trend toward shorter laser times.
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INTRODUCTION
Photoselective vaporisation of the prostate (PVP) has become 
an established form of treatment for benign prostatic obstruc-
tion and to date has demonstrated equivalence to transurethral 
resection of the prostate in randomised controlled trials [1-4]. 
Since PVP became commercially available in 2001, there have 
been two further versions of the technology characterised by 
increased power and improved laser fibre technology. The 
120W lithium triborate (LBO) laser entered clinical use in late 
2006 and was followed by the 180W LBO laser in late 2010. 
With the 50% increase in power, there was a corresponding 
50% increase in the diameter of the laser beam resulting in no 
change in the power density. A significant change, apart from 
increased power, was the development of a liquid cooled fi-
bre, an automated system to shut down power with overheat-
ing of the fibre and new coagulation settings that provide a 
pulsed rather than quasi-continuous low power mode.
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 There is little data available on the performance of the 
180W LBO laser. Published clinical data would suggest that 
the 180W laser safe and efficacious [5]. The impact of the 
transition of the new laser to an experienced PVP surgeon has 
not previously been reported. The objective was to compare 
the early experience of an experienced PVP surgeon’s first 
50 cases with the 180W LBO laser with the last 50 cases per-
formed with the 120W LBO laser.
MATERIALS AND METHODS
All PVP cases performed by a single surgeon (HHW) have 
been prospectively maintained. The last 50 cases treated with 
the 120W LBO had undergone treatment at the Sydney Ad-
ventist Hospital between December 2009 and August 2010. 
The first 50 cases treated with the 180W LBO laser were per-
formed at the same institution between July 2010 and June 
2011. Only 3 cases using the 180W LBO laser were performed 
in the overlap period between July and August 2010. Subse-
quent to completing the last 120W LBO laser case in August 
2010, no further cases were performed.
 The surgical technique was the same for both types of laser 
and was consistent with the technique previously described 
by the International Greenlight Users Group [6]. A working 
channel was created at 80W power setting and this was im-
mediately increased to 120W power once there was sufficient 
working space created. In the case of 180W LBO laser, the 
power was increased further from 120W to 180W as soon as 
there was sufficient space. 
 The inclusion criteria were all men undergoing PVP for 
indications consistent with established guidelines for surgery 
for benign prostatic hyperplasia [7,8]. Men with a history of 
prostate cancer were excluded from analysis. 
 Baseline variables are summarised in Table 1. Men in uri-
nary retention had all failed trial of voids and could not have 
baseline flow data and symptoms scores recorded. Preopera-
tive and postoperative parameters at 3 months compared 
included the International Prostate Symptom Score (IPSS), 
quality of life (QoL) index, peak urinary flow (Qmax), post 
void residual (PVR) urine as measured by transabdominal 
ultrasound. 
 Statistical analyses were performed using the Statistical 
Online Computational Resource (http://www.socr.ucla.edu). 
Paired analysis was performed using the Student t-test and for 
non-parametric analyses, the Mann-Whitney test was used. 
Statistical significance was defined at the level of P<0.05.
RESULTS
Perioperative data is summarised in Table 2. There was simi-
lar utilisation of power relative to prostate volume between 
the two laser powers. The laser and operating time relative to 
the total transrectal ultrasound measured prostate volume 
was significantly decreased.
 Not all patients attended follow-up at 3 months. In total 5 
patients in the 180W group did not attend because they either 
missed their appointment, did not live in the area and one 
patient died from an unrelated cause. The 120W had 8 patients 
who did not attend follow-up (3 missed appointment, 3 did 
not live within the area and 2 did not want further follow-up).
 Changes in functional parameters such as the IPSS, QoL, 
Qmax and PVR are summarised in Table 3 where paired 
analysis has been performed for those men who were able to 
attend follow-up and were not in urinary retention prior to 
surgery. These values did not result in statistical significance.
For men in urinary retention, 3 of the 6 (including 2 lost to 
follow-up) and 7 of 7 of men treated with the 120W and 180W 
LBO laser respectively were able to successfully void follow-
ing removal of their catheters. The postoperative IPSS, QL, 
Qmax and PVR respectively was not different between those 
Table 1. Baseline patient variables
Variable First 50–180W Last 50–120W P-value
Age (yr) 66.5 (60–71.8) 68 (60–73.8) 0.216
TRUS volume (mL) 68 (45.5–94.0) 51 (37.8–72.3) 0.017
ASA score 2.0 (2.0–2.0) 2.0 (2.0–2.0) 0.791
Prostate specific antigen 3.55 (1.7–7.3) 3.40 (1.7–4.9) 0.132
Acute urinary retention 7 6
Values are presented as median (interquartile range). 
TRUS, transrectal ultrasound; ASA, American Society of Anesthesiolo-
gists.
Table 2. Perioperative parameters 
Parameter First 50–180W Last 50–120W % P-value
Total operation 
time (min)
56 (46–78.5) 65 (49.5–92) -13.8 0.193
Laser time (min) 45 (33–63) 50 (35–72.5) -10 0.332
Laser time per 
gram prostate 
(min/mL)
0.67 (0.52–0.79) 1.0 (0.73–1.19) -33 <0.001
Laser energy (kJ) 400 (301.8–601) 343 (220.8–512.5) +17 0.031
Laser energy per 
gram prostate 
(kJ/g)
6.1 (4.8–7.6) 6.4 (4.97–7.97) -5 0.537
Duration IDC (hr) 12 (11–14.8) 14 (12–16) -14 0.072
Post operation 
stay (hr)
18 (16.3–20.8) 19 (16–20.5) -5 0.403
Values are presented as median (interquartile range). 
IDC, indwelling catheter.
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treated with either the 120W or 180W LBO laser. 
 Complications did differ between the two lasers as outlined 
in Table 4 below. These are summarised using the Clavien-
Dindo classification for surgical complications. 
DISCUSSION
Men treated with the 120W or 180W LBO laser have similar 
post operative outcomes with this early experience.
 For the surgeon, there are significantly noticeable changes 
with the transition to the 180W LBO laser. The cystoscope 
hardware and video camera set up is unchanged but the 
cooled irrigated laser fiber associated with the 180W machine 
is larger in diameter at 750 microns compared to the diameter 
of the 120W laser fiber which has a diameter of 600 microns. 
This slightly reduces the endoscopic field of view and the 
cross sectional area of the cystoscope continuous flow chan-
nel available for irrigation. The power density is proportional 
to the power of the laser and inversely proportional to the 
cross sectional area of the laser beam. The 50% increase in 
laser beam diameter and the 50% increase in power maintain 
the same power density compared to the 120W laser fiber but 
is associated with a larger quantity of vaporization bubbles 
being produced which can potentially impact upon visibility. 
Whilst initial familiarity with these changes was necessary, 
it did not impact upon the ability to adapt to the new laser. 
Further investigation is required to determine the impact of 
a surgeon without prior experience with lower powered PVP 
dealing with these issues. Anecdotal experience from col-
leagues adopting PVP using the 180W LBO laser for the first 
time does not appear to be associated with reported problems.
 All men were treated within a 12-month period of time. 
The laser technique was consistent throughout the 12 months 
and compared the last 50 120W cases with the first 180W 
with a surgeon who had already substantial PVP experience. 
This transition provides a meaningful comparison for the 
experienced surgeon with the 120W LBO laser considering 
the transition to the higher powered laser. This study suggests 
that this transition is possible without significant change in 
outcomes and unlikely concerns associated with relearning 
PVP with a new laser.
 One major complication of capsular perforation occurred 
using the 180W LBO laser. This had not previously been ob-
served in the 120W LBO experience. It is a technically related 
complication due to the failure to recognise excessive depth 
of vaporisation, particularly at the region of the bladder neck. 
A much larger experience from a broad number of centers 
with large volume experience will be necessary to determine 
it this occurring in increased numbers compared to historical 
published experience with the 120W LBO laser. On the basis 
that the power density is unchanged, the 180W LBO laser will 
not vaporise deeper than the 120W LBO laser in the equiva-
lent duration of application of laser energy to tissue. It is our 
belief from this early experience, that this is a sporadic occur-
rence little different to what has been reported with the 120W 
LBO laser.
 There is little surprise that clinical outcomes are similar be-
tween the two lasers. The differences could be compared to 
the analogy of using a paintbrush to paint a wall and switch-
ing to paintbrush that is 50% wider and thereby reducing 
Table 3. Paired analysis of results 
Parameter
First 50–180W Last 50–120W
Before 3 mo % Before 3 mo %
PSA (ng/mL) 3.55 (1.7–7.3) 1.4 (0.82–2.70) -61 3.40 (1.7–4.9) 1.13 (0.78–1.89) -67
IPSS 20 (14–25) 7 (4–14) -65 21 (17–26) 9 (5–12) -57
Quality of life 4 (4–5) 2 (1,3) +50 4 (4–5) 2 (1–2) +50
Qmax (mL/sec) 9 (6.2–12.2) 26 (20.2–36) +189 9 (7–11) 24 (16.5–32.45) +167
Post void residual (mL) 143 (63–260) 32 (0–60) -78 110 (74.5–195.5) 15 (0–60) -86
IIEF 21.5 (16–24.8) 19 (15–24) -12 19 (10.8–22.3) 18 (8–21.5) -5
Acute urinary retention 7 7 Voiding 6 3 Voiding
Values are presented as median (interquartile range). 
PSA, prostate specific antigen; IPSS, International Prostate Symptom Score; Qmax, peak urinary flow; IIEF, index of erectile function.
Table 4. Complications
First 50–180W
Clavien 
Dindo
Last 50–120W
Clavien 
Dindo
Clot retention×2 1 Urinary tract infection×2 1
Febrile 1 Intermittent self catheteri-
sation×2
1
Retention 1 Blood transfusion (1 unit) 2
Capsular perforation 3b
Bladder neck contrac-
ture×2
3b
Urethral stricture 3b
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the time taken. In clinical practice, a reduction in operating 
time may not occur. It is our belief that this improvement in 
operating time may be compensated by the use of a greater 
amount of energy to treat the same prostate gland volume 
and therefore enabling a greater and more efficient removal 
of tissue. Our early results reflect this behaviour where the 
laser time per gram of prostate is reduced by 33% and the 
total laser time is reduced by 5 minutes and overall operating 
by 8 minutes. This relative modest improvement in time may 
be due to the learning curve of the 180W laser and may still 
improve with further case experience. It is our opinion that 
this effect may potentially be more likely observed with larger 
prostates where fibre degradation and surgeon fatigue could 
potentially lead to limitation of the amount of energy utilised 
to treat a large gland. 
 In conclusion, this study demonstrates that there is little 
change in clinical outcomes with the transition from 120W 
to 180W LBO PVP with an already experienced PVP surgeon. 
The introduction of the more powerful 180W LBO laser ap-
pears to have impacted upon patient selection with signifi-
cantly increased prostate size and associated with increased 
energy utilisation. There is a trend toward shorter laser times. 
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